Recent findings concerning thiazolidinediones in the treatment of diabetes (Q36407304)

14 August 2017

1 reference

title

Recent findings concerning thiazolidinediones in the treatment of diabetes (English)

1 reference

14 August 2017

Guenther Boden

1

1 reference

PubMed ID

16503761

14 August 2017

Meijuan Zhang

series ordinal

2

1 reference

PubMed ID

16503761

14 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

Expert Opinion on Investigational Drugs

14 August 2017

1 reference

14 August 2017

15

1 reference

14 August 2017

3

1 reference

14 August 2017

243-250

1 reference

The mechanisms of action of PPARs

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Effect of troglitazone on leptin production. Studies in vitro and in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Therapeutic potential of thiazolidinediones as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Peroxisome proliferator-activated receptor gamma and metabolic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Lipids and glucose in type 2 diabetes: what is the cause and effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Prevention of fat-induced insulin resistance by salicylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Lessons from the glitazones: a story of drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Clinical practice. Initial management of glycemia in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Thiazolidinediones, Peripheral Edema, and Type 2 Diabetes: Incidence, Pathophysiology, and Clinical Implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Possible heart failure exacerbation associated with rosiglitazone: case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Attenuation of accumulation of neointimal lipid by pioglitazone in mice genetically deficient in insulin receptor substrate-2 and apolipoprotein E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Expression and function of PPARgamma in rat and human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Therapeutic roles of peroxisome proliferator-activated receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Association of nonalcoholic fatty liver disease with insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Insulin-lowering drugs in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical mode

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

PPARalpha activators inhibit tissue factor expression and activity in human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.3.243

10.1517/13543784.15.3.243

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16503761